Publications

Detailed Information

Effect of Postoperative Radiotherapy after Primary Tumor Resection in De Novo Stage IV Breast Cancer: A Multicenter Retrospective Study (KROG 19-02)

Cited 3 time in Web of Science Cited 4 time in Scopus
Authors

Kim, Yeon Joo; Kim, Yeon-Joo; Kim, Yong Bae; Lee, Ik Jae; Kwon, Jeanny; Kim, Kyubo; Cha, Jihye; Kim, Myungsoo; Jo, In Young; Kim, Jung Hoon; Park, Jaehyeon; Kim, Jin Hee; Kim, Juree; Shin, Kyung Hwan; Kim, Su Ssan

Issue Date
2022-04
Publisher
대한암학회
Citation
Cancer Research and Treatment, Vol.54 No.2, pp.478-487
Abstract
Purpose This study aimed to investigate the impact of postoperative radiotherapy (PORT) in de novo metastatic breast cancer (dnMBC) patients undergoing planned primary tumor resection (PTR) and to identify the subgroup of patients who would most benefit Materials and Methods This study enrolled 426 patients with dnMBC administered PTR alone or with PORT. The primary and secondary outcomes were overall and progression-free survival (OS and PFS), respectively. Results The median follow-up time was 53.7 months (range, 3.1 to 194.4). The 5-year OS and PFS rates were 73.2% and 32.0%, respectively. For OS, clinical T3/4 category, triple-negative breast cancer (TNBC), postoperative chemotherapy alone were significantly poor prognostic factors, and administration of PORT failed to show its significance. Regarding PFS, PORT was a favorable prognostic factor (hazard ratio, 0.64; 95% confidence interval, 0.50 to 0.82; p < 0.001), in addition to T1/2 category, <= 5 metastases, and nonTNBC. According to the multivariate analyses of OS in the PORT group, we divided the patients into three groups (group 1, T1/2 and non-TNBC [n=193]; group 2, T3/4 and non-TNBC [n=171]; and group 3, TNBC [n=49]), and evaluated the effect of PORT. Although PORT had no significance for OS in all subgroups, it was a significant factor for good prognosis regarding PFS in groups 1 and 2, not in group 3. Conclusion PORT was associated with a significantly better PFS in patients with dnMBC who underwent PTR. Patients with clinical T1/2 category and non-TNBC benefited most from PORT, while those with TNBC showed little benefit.
ISSN
1598-2998
URI
https://hdl.handle.net/10371/182756
DOI
https://doi.org/10.4143/crt.2021.632
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share